Biotech Startups

Vail Scientific develops VSNO, a non-invasive, point-of-care diagnostic tool for rapid screening of patients suspected of having sepsis to aid in triage. The company serves healthcare providers with medical technology aimed at earlier sepsis diagnosis.

1 investor

Valbiotis develops patented, clinically-tested dietary supplements focused on cardiometabolic health and everyday wellness concerns such as sleep, fatigue, immunity, mood, and vitality. Its plant-based formulas, backed by over a decade of research, are designed for health professionals and consumers and are made in France.

1 investor

Valen designs drugs using computational biology and experimental data generation. The company serves pharmaceutical and biotech researchers developing the next generation of therapeutics.

1 investor

VALFIX develops a transcatheter mitral valve repair system with a robotic interface, designed to convert open-heart valve surgery into a minimally invasive transcatheter procedure. The technology targets patients with mitral valve disease and heart failure.

1 investor

ValGenesis offers an AI-enabled digital validation platform for the life sciences industry, covering the full lifecycle of drug process design, validation, and continuous process monitoring. Its software is used by pharmaceutical and biotech companies to manage GxP validation, cleaning validation, CMC/QbD development, and continued process verification.

1 investor

Vali provides an AI-assisted platform for karyotyping analysis, where users upload metaphase images and receive cytogenetic results within 24 hours. It serves cytogenetics labs and clinicians, combining artificial intelligence with expert review in the healthtech/diagnostics space.

1 investor

VALID builds human iPSC-derived co-culture disease models and pairs them with automated high-throughput perturbation screening and multimodal measurement (imaging, RNA-seq, proteomics) to generate AI-ready biological data for drug discovery. Its platform aims to produce more human-relevant, predictive hypotheses and targets for pharmaceutical development.

1 investor

1 investor

Valius is a molecular oncology company that develops tools to understand cancer cell behavior and enable targeted drug development and personalized therapies. It serves clinical and pharmaceutical organizations focused on improving cancer treatment outcomes.

1 investor

ValleyDAO provides funding and community support to research scientists and entrepreneurs developing unconventional biotech projects, offering grants up to $250k with rapid turnaround and access to a network of investors and thought leaders.

1 investor

Valorum is a biosimilars company focused on commercializing biosimilar therapies with an emphasis on supply continuity, disciplined pricing, and buy-and-bill partnership models for physician practices, with an initial focus on oncology and ophthalmology. It serves clinicians and specialty care practices in the United States.

1 investor

ValoTx develops oncolytic virus-based immunotherapies that combine viral vector technology with peptide vaccination to treat cancer. The company leverages a patented platform to rapidly create personalized and disease-specific immunotherapies targeting multiple cancer types.

1 investor

Valted Seq builds an end-to-end single cell analysis platform using robotics and AI, and has assembled a large database of single cell brain samples to support biomarker and therapeutic target discovery. It focuses on neurodegenerative diseases such as Alzheimer's and Parkinson's for use in healthcare and life sciences research.

1 investor

Valthos develops AI systems to identify biological threats and design medical countermeasures in real time for biodefense applications.

1 investor

A biomanufacturing company with deep expertise in bioprocessing, process development, and chemically-defined media systems, led by a team of scientists with extensive experience in cell therapy and biologics manufacturing.

1 investor

Vanda is a biopharmaceutical company that develops new medicines, using genetics and genomics to guide drug discovery, clinical trials, and commercial positioning of its compounds. It works to advance novel approaches for delivering these medicines to patients.

1 investor

VanDeMark is a specialty chemicals manufacturer that produces phosgene-based chemical intermediates and performs custom complex chemical synthesis, including phosgenation, chlorination, hydrazine, acylation, and esterification. It supplies the materials, life sciences, and consumer markets with customized chemical intermediates for demanding applications.

1 investor

Drug development company creating small-molecule procaspase-3 activators as targeted oncology therapeutics.

1 investor

Vantage Biosciences develops clinical-stage drug therapies for retinal and other diseases, with a focus on the AOC3 target and its role in liver and eye disease. The company works with a network of preclinical and clinical experts to advance therapeutics where existing treatment options are limited.

1 investor

Vantage Group develops release agents and related formulations used in food production lines to prevent products from sticking to equipment during baking and processing. It serves plant managers and manufacturers of baked and processed foods.

1 investor

Vapogenix is a pharmaceutical developer creating non-opioid pain relief therapies designed for rapid onset and long-lasting effect.

1 investor

Vapore makes Mypurmist, a cordless handheld steam inhaler and air purifier marketed as a drug-free remedy for allergies, sinus congestion, colds, flu and throat and vocal health. The company also offers Mypurskin, a light-therapy skin rejuvenation device, selling consumer respiratory and skincare wellness products to individuals and families.

1 investor

1 investor

VascuBio Innovation develops microfluidics, biomaterials, and biofabrication platforms—including bioreactors, screening systems, and organ-on-chip technologies—for drug screening, tissue engineering, and regenerative medicine. Founded on academic research connected to McGill University, it serves researchers and industry seeking human-relevant in vitro models that reduce reliance on animal testing.

1 investor